drugset / Trial / NCT01910064

A Long Term Study of GK530G in Subjects With Acne Vulgaris

NCT01910064

Phase 3 Completed 436 enrolled Galderma R&D
NaSingle-groupOpen-labelTreatment

Summary

This open label study is to determine the safety profile of GK530G in a long-term treatment (up to 12 months) in subjects with acne vulgaris and to evaluate the efficacy of GK530G in a long-term treatment.

Timeline

Start
2013-05
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Adapalene Other / unclassified
Subject Benzoyl Peroxide Other / unclassified

Indications